323 related articles for article (PubMed ID: 30688661)
1. Selective tissue targeting of synthetic nucleic acid drugs.
Seth PP; Tanowitz M; Bennett CF
J Clin Invest; 2019 Mar; 129(3):915-925. PubMed ID: 30688661
[TBL] [Abstract][Full Text] [Related]
2. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.
Bennett CF; Swayze EE
Annu Rev Pharmacol Toxicol; 2010; 50():259-93. PubMed ID: 20055705
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotides for the treatment of dyslipidaemia.
Visser ME; Witztum JL; Stroes ES; Kastelein JJ
Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
[TBL] [Abstract][Full Text] [Related]
4. Targeted Delivery of Antisense Oligonucleotides Using Neurotensin Peptides.
Nikan M; Tanowitz M; Dwyer CA; Jackson M; Gaus HJ; Swayze EE; Rigo F; Seth PP; Prakash TP
J Med Chem; 2020 Aug; 63(15):8471-8484. PubMed ID: 32677436
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects.
Rigo F; Seth PP; Bennett CF
Adv Exp Med Biol; 2014; 825():303-52. PubMed ID: 25201110
[TBL] [Abstract][Full Text] [Related]
6. Targeting the expression of anti-apoptotic proteins by antisense oligonucleotides.
Delihas N
Curr Drug Targets; 2001 Jun; 2(2):167-80. PubMed ID: 11469717
[TBL] [Abstract][Full Text] [Related]
7. Antisense applications for biological control.
Pan WH; Clawson GA
J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
[TBL] [Abstract][Full Text] [Related]
8. Advances in therapeutic bacterial antisense biotechnology.
Hegarty JP; Stewart DB
Appl Microbiol Biotechnol; 2018 Feb; 102(3):1055-1065. PubMed ID: 29209794
[TBL] [Abstract][Full Text] [Related]
9. Modulation of lipoprotein metabolism by antisense technology: preclinical drug discovery methodology.
Crooke RM; Graham MJ
Methods Mol Biol; 2013; 1027():309-24. PubMed ID: 23912993
[TBL] [Abstract][Full Text] [Related]
10. Unlocking the potential of chemically modified peptide nucleic acids for RNA-based therapeutics.
Pradeep SP; Malik S; Slack FJ; Bahal R
RNA; 2023 Apr; 29(4):434-445. PubMed ID: 36653113
[TBL] [Abstract][Full Text] [Related]
11. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
[TBL] [Abstract][Full Text] [Related]
12. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.
Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A
J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624
[TBL] [Abstract][Full Text] [Related]
13. Toxicology of antisense therapeutics.
Jason TL; Koropatnick J; Berg RW
Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
[TBL] [Abstract][Full Text] [Related]
14. Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics.
Arora V; Devi GR; Iversen PL
Curr Pharm Biotechnol; 2004 Oct; 5(5):431-9. PubMed ID: 15544491
[TBL] [Abstract][Full Text] [Related]
15. Use of antisense oligonucleotides: advantages, controls, and cardiovascular tissue.
Golden T; Dean NM; Honkanen RE
Microcirculation; 2002 Jan; 9(1):51-64. PubMed ID: 11896559
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of antisense oligonucleotides to pancreatic β-cells.
Ämmälä C; Drury WJ; Knerr L; Ahlstedt I; Stillemark-Billton P; Wennberg-Huldt C; Andersson EM; Valeur E; Jansson-Löfmark R; Janzén D; Sundström L; Meuller J; Claesson J; Andersson P; Johansson C; Lee RG; Prakash TP; Seth PP; Monia BP; Andersson S
Sci Adv; 2018 Oct; 4(10):eaat3386. PubMed ID: 30345352
[TBL] [Abstract][Full Text] [Related]
17. Antisense technology: an overview and prospectus.
Crooke ST; Baker BF; Crooke RM; Liang XH
Nat Rev Drug Discov; 2021 Jun; 20(6):427-453. PubMed ID: 33762737
[TBL] [Abstract][Full Text] [Related]
18. Making sense of antisense oligonucleotides: A narrative review.
Goyal N; Narayanaswami P
Muscle Nerve; 2018 Mar; 57(3):356-370. PubMed ID: 29105153
[TBL] [Abstract][Full Text] [Related]
19. Overcoming the challenges of tissue delivery for oligonucleotide therapeutics.
Gökirmak T; Nikan M; Wiechmann S; Prakash TP; Tanowitz M; Seth PP
Trends Pharmacol Sci; 2021 Jul; 42(7):588-604. PubMed ID: 34020790
[TBL] [Abstract][Full Text] [Related]
20. Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics.
Zhou T; Kim Y; MacLeod AR
Methods Mol Biol; 2016; 1402():199-213. PubMed ID: 26721493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
